Exploring the scope and challenges of palliative care among patients and caregivers in Bhubaneswar, Odisha, India: A qualitative inquiry
Authors
- Jyana Ranjan MohapatraDepartment of Management Sciences, Siksha O Anusandhan (Deemed to be University), Bhubaneswar, Odisha, India
- Manoranjan DashDepartment of Management Sciences, Siksha O Anusandhan (Deemed to be University), Bhubaneswar, Odisha, India
- Satish SadangiDepartment of Palliative Medicine, Bagchi Karunashraya Palliative Care Centre, Bhubaneswar, Odisha, India
- Viswanatha JagannathDepartment of Palliative Medicine, Bagchi Karunashraya Palliative Care Centre, Bhubaneswar, Odisha, India
DOI:
Keywords
Downloads
Correspondence
Publication history
Responsible editor
Reviewer
Funding
Ethical approval
Trial registration number
Copyright
Published by Bangladesh Medical University (former Bangabandhu Sheikh Mujib Medical University).
Palliative care remains severely underutilised in India, where over five million individuals require such services annually yet coverage spans only a fraction of this need, with the largest deficits concentrated in eastern states [1]. India’s National Programme for Palliative Care has achieved meaningful penetration only in select districts; access across Odisha is critically constrained by workforce shortages, limited public awareness, and inadequate infrastructure. Odisha, despite its substantial cancer burden, lacks organised palliative care delivery beyond its capital, Bhubaneswar. Family caregivers shoulder the primary burden of end-of-life care in this context, yet no qualitative study had examined their lived experiences within specialist palliative settings in the state. This study aimed to explore caregiver experiences across symptom management, the healthcare environment, communication, psychosocial and spiritual support, and caregiver burden at two specialist palliative care units in Bhubaneswar.
Table 1 Themes, sub-themes, illustrative codes, and theoretical framework anchors
Theme | Sub-theme | Illustrative codes | Theoretical anchor |
1. Initial unawareness of palliative care | a. Pre-referral unawareness | Never heard of palliative care; equated with dying; relief after orientation | Health Literacy Model; Kleinman’s Explanatory Model |
2. Satisfaction with symptom management | a. Pain control | Pain-free; confidence in medication; side-effect management | WHOa Pain Ladder; Donabedian Framework |
3. Healthcare environment | a. Homelike ambience | Peaceful; clean; domestic warmth; safe facilities | IHIb Safety Framework; Evidence-Based Design |
4. Communication, coordination, and home-based training | a. Proactive communication | Informed daily; never left in the dark; trained for home care | Person-Centred Care Framework; Caregiver Self-Efficacy Theory |
5. Psychosocial, emotional, and spiritual support | a. Emotional counselling | Restored coping capacity; pooja facilitated; grief normalised | Lazarus and Folkman Stress-Coping Model; FICAcTool; Worden’s Tasks of Mourning |
6. End-of-life care and caregiver burden | a. Dignified dying | Peaceful death; cultural respect; training reduced helplessness | Good Death Framework; Caregiver Self-Efficacy Theory |
aWorld Health Organization;bInstitute for Healthcare Improvement; cThe FICA tool is a structured framework used by healthcare providers to assess a patient’s spirituality, standing for Faith, Importance or Influence, Community, and Address or Action | |||
Six themes were identified across 15 sub-themes (Table 1): (1) initial unawareness of palliative care; (2) high satisfaction with symptom management; (3) positive perception of the healthcare environment; (4) effective communication, coordination, and home-based training; (5) meaningful psychosocial, emotional, and spiritual support; and (6) end-of-life care and caregiver burden. All ten caregivers reported complete pre-referral unawareness, with cultural stigma equating palliative care with imminent death compounding access barriers — consistent with All India Institute of Medical Sciences (AIIMS) New Delhi data in which the majority of advanced cancer outpatients had not previously heard the term “palliative care” [4]. A representative caregiver from Kandhamal district described: “My relatives said, why are you taking her there? That is the place for those who are about to die.” All caregivers described a transformative shift from fear to understanding and relief following structured team orientation. The healthcare environment was rated 3–5 out of 5 and consistently characterised as qualitatively distinct from conventional hospital settings — peaceful, clean, and domestically warm — features identified as essential components of healing in Indian palliative care settings [5]. Pain control was rated 4–5 out of 5 by all participants, a notably high finding given documented opioid access barriers in India. Proactive communication and structured home-based caregiver training — encompassing analgesic administration, wound care, nutritional guidance, repositioning, and emergency escalation — were rated 4–5 out of 5 and substantially reduced caregiver burden, consistent with Kerala home-based palliative care evidence [6]. Spiritual care, including facilitation of prayer, pooja, and culturally appropriate bereavement counselling, was integral to coping [7]. Despite high overall satisfaction (3–5 out of 5 across all domains), all caregivers reported substantial physical and emotional burden, most pronounced among those with limited home-based support.


Variables | Frequency (%) |
Indication of colposcopy |
|
Visual inspection of the cervix with acetic acid positive | 200 (66.7) |
Abnormal pap test | 13 (4.3) |
Human papilloma virus DNA positive | 4 (1.3) |
Suspicious looking cervix | 14 (4.7) |
Others (per vaginal discharge, post-coital bleeding) | 69 (23.0) |
Histopathological diagnosis | |
Cervical Intraepithelial Neoplasia 1 | 193 (64.3) |
Cervical Intraepithelial Neoplasia 2 | 26 (8.7) |
Cervical Intraepithelial Neoplasia 3 | 32 (10.7) |
Invasive cervical cancer | 27 (9.0) |
Chronic cervicitis | 17 (5.6) |
Squamous metaplasia | 5 (1.7) |
Groups based on pre-test marks | Pretest | Posttest Marks (%) | Difference in pre and post-test marks (mean improvement) | P |
Didactic lecture classes | ||||
<50% | 36.6 (4.8) | 63.2 (9.4) | 26.6 | <0.001 |
≥50% | 52.8 (4.5) | 72.4 (14.9) | 19.6 | <0.001 |
Flipped classes | ||||
<50% | 36.9 (4.7) | 82.2 (10.8) | 45.4 | <0.001 |
≥50% | 52.8 (4.6) | 84.2 (10.3) | 31.4 | <0.001 |
Data presented as mean (standard deviation) | ||||
Background characteristics | Number (%) |
Age at presentation (weeks)a | 14.3 (9.2) |
Gestational age at birth (weeks)a | 37.5 (2.8) |
Birth weight (grams)a | 2,975.0 (825.0) |
Sex |
|
Male | 82 (41) |
Female | 118 (59) |
Affected side |
|
Right | 140 (70) |
Left | 54 (27) |
Bilateral | 6 (3) |
Delivery type |
|
Normal vaginal delivery | 152 (76) |
Instrumental delivery | 40 (20) |
Cesarean section | 8 (4) |
Place of delivery |
|
Home delivery by traditional birth attendant | 30 (15) |
Hospital delivery by midwife | 120 (60) |
Hospital delivery by doctor | 50 (25) |
Prolonged labor | 136 (68) |
Presentation |
|
Cephalic | 144 (72) |
Breech | 40 (20) |
Transverse | 16 (8) |
Shoulder dystocia | 136 (68) |
Maternal diabetes | 40 (20) |
Maternal age (years)a | 27.5 (6.8) |
Parity of mother |
|
Primipara | 156 (78) |
Multipara | 156 (78) |
aMean (standard deviation), all others are n (%) | |
Background characteristics | Number (%) |
Age at presentation (weeks)a | 14.3 (9.2) |
Gestational age at birth (weeks)a | 37.5 (2.8) |
Birth weight (grams)a | 2,975.0 (825.0) |
Sex |
|
Male | 82 (41) |
Female | 118 (59) |
Affected side |
|
Right | 140 (70) |
Left | 54 (27) |
Bilateral | 6 (3) |
Delivery type |
|
Normal vaginal delivery | 152 (76) |
Instrumental delivery | 40 (20) |
Cesarean section | 8 (4) |
Place of delivery |
|
Home delivery by traditional birth attendant | 30 (15) |
Hospital delivery by midwife | 120 (60) |
Hospital delivery by doctor | 50 (25) |
Prolonged labor | 136 (68) |
Presentation |
|
Cephalic | 144 (72) |
Breech | 40 (20) |
Transverse | 16 (8) |
Shoulder dystocia | 136 (68) |
Maternal diabetes | 40 (20) |
Maternal age (years)a | 27.5 (6.8) |
Parity of mother |
|
Primipara | 156 (78) |
Multipara | 156 (78) |
aMean (standard deviation), all others are n (%) | |
Mean escape latency of acquisition day | Groups | ||||
NC | SC | ColC | Pre-SwE Exp | Post-SwE Exp | |
Days |
|
|
|
|
|
1st | 26.2 (2.3) | 30.6 (2.4) | 60.0 (0.0)b | 43.2 (1.8)b | 43.8 (1.6)b |
2nd | 22.6 (1.0) | 25.4 (0.6) | 58.9 (0.5)b | 38.6 (2.0)b | 40.5 (1.2)b |
3rd | 14.5 (1.8) | 18.9 (0.4) | 56.5 (1.2)b | 34.2 (1.9)b | 33.8 (1.0)b |
4th | 13.1 (1.7) | 17.5 (0.8) | 53.9 (0.7)b | 35.0 (1.6)b | 34.9 (1.6)b |
5th | 13.0 (1.2) | 15.9 (0.7) | 51.7 (2.0)b | 25.9 (0.7)b | 27.7 (0.9)b |
6th | 12.2 (1.0) | 13.3 (0.4) | 49.5 (2.0)b | 16.8 (1.1)b | 16.8 (0.8)b |
Average of acquisition days | |||||
5th and 6th | 12.6 (0.2) | 14.6 (0.8) | 50.6 (0.7)b | 20.4 (2.1)a | 22.4 (3.2)a |
NC indicates normal control; SC, Sham control; ColC, colchicine control; SwE, swimming exercise exposure. aP <0.05; bP <0.01. | |||||
Categories | Number (%) |
Sex |
|
Male | 36 (60.0) |
Female | 24 (40.0) |
Age in yearsa | 8.8 (4.2) |
Education |
|
Pre-school | 20 (33.3) |
Elementary school | 24 (40.0) |
Junior high school | 16 (26.7) |
Cancer diagnoses |
|
Acute lymphoblastic leukemia | 33 (55) |
Retinoblastoma | 5 (8.3) |
Acute myeloid leukemia | 4 (6.7) |
Non-Hodgkins lymphoma | 4 (6.7) |
Osteosarcoma | 3 (5) |
Hepatoblastoma | 2 (3.3) |
Lymphoma | 2 (3.3) |
Neuroblastoma | 2 (3.3) |
Medulloblastoma | 1 (1.7) |
Neurofibroma | 1 (1.7) |
Ovarian tumour | 1 (1.7) |
Pancreatic cancer | 1 (1.7) |
Rhabdomyosarcoma | 1 (1.7) |
aMean (standard deviation) | |



Test results | Disease | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | ||
Yes | No | ||||||
Reid’s score ≥ 5 | Positive | 10 | 15 | 37.0 | 94.5 | 40.1 | 93.8 |
Negative | 17 | 258 |
|
|
|
| |
Swede score ≥ 5 | Positive | 20 | 150 | 74.1 | 45.0 | 11.8 | 94.6 |
Negative | 7 | 123 |
|
|
|
| |
Swede score ≥ 8 | Positive | 3 | 21 | 11.1 | 92.3 | 12.5 | 91.3 |
Negative | 24 | 252 |
|
|
|
| |
a High-grade indicates a score of ≥5 in both tests; PPV indicates positive predictive value; NPV, negative predictive value | |||||||
Test | Sensitivity (%) | Specificity (%) | Positive predictive value (%) | Negative predictive value (%) |
Reid’s score ≥ 5 | 37.0 | 94.5 | 40.0 | 93.8 |
Swede score ≥ 5 | 74.1 | 45 | 11.8 | 94.6 |
Swede score ≥ 8 | 11.1 | 92.3 | 12.5 | 91.3 |
Test | Sensitivity (%) | Specificity (%) | Positive predictive value (%) | Negative predictive value (%) |
Reid’s score ≥ 5 | 37.0 | 94.5 | 40.0 | 93.8 |
Swede score ≥ 5 | 74.1 | 45 | 11.8 | 94.6 |
Swede score ≥ 8 | 11.1 | 92.3 | 12.5 | 91.3 |
Narakas classification | Total 200 (100%) | Grade 1 72 (36%) | Grade 2 64 (32%) | Grade 3 50 (25%) | Grade 4 14 (7%) |
Complete recoverya | 107 (54) | 60 (83) | 40 (63) | 7 (14) | - |
Near complete functional recovery but partial deformitya | 22 (11) | 5 (7) | 10 (16) | 6 (12) | 1 (7) |
Partial recovery with gross functional defect and deformity | 31 (16) | 7 (10) | 13 (20) | 10 (20) | 1 (7) |
No significant improvement | 40 (20) | - | 1 (1.5) | 27 (54) | 12 (86) |
aSatisfactory recovery bGrade 1, C5, 6, 7 improvement; Grade 2, C5, 6, 7 improvement; Grade 3, panpalsy C5, 6, 7, 8, 9, Grade 4, panpalsy with Hornon’s syndrome. | |||||
Narakas classification | Total 200 (100%) | Grade-1 72 (36%) | Grade-2 64 (32%) | Grade-3 50 (25%) | Grade-4 14 (7%) |
Complete recoverya | 107 (54) | 60 (83) | 40 (63) | 7 (14) | - |
Near complete functional recovery but partial deformitya | 22 (11) | 5 (7) | 10 (16) | 6 (12) | 1 (7) |
Partial recovery with gross functional defect and deformity | 31 (16) | 7 (10) | 13 (20) | 10 (20) | 1 (7) |
No significant improvement | 40 (20) | - | 1 (1.5) | 27 (54) | 12 (86) |
aSatisfactory recovery bGrade 1, C5, 6, 7 improvement; Grade 2, C5, 6, 7 improvement; Grade 3, panpalsy C5, 6, 7,8,9, Grade 4, panpalsy with Hornon’s syndrome. | |||||
Variables in probe trial day | Groups | ||||
NC | SC | ColC | Pre-SwE Exp | Post-SwE Exp | |
Target crossings | 8.0 (0.3) | 7.3 (0.3) | 1.7 (0.2)a | 6.0 (0.3)a | 5.8 (0.4)a |
Time spent in target | 18.0 (0.4) | 16.2 (0.7) | 5.8 (0.8)a | 15.3 (0.7)a | 15.2 (0.9)a |
NC indicates normal control; SC, Sham control; ColC, colchicine control; SwE, swimming exercise exposure. aP <0.01. | |||||
Pain level | Number (%) | P | ||
Pre | Post 1 | Post 2 | ||
Mean (SD)a pain score | 4.7 (1.9) | 2.7 (1.6) | 0.8 (1.1) | <0.001 |
Pain categories | ||||
No pain (0) | - | 1 (1.7) | 31 (51.7) | <0.001 |
Mild pain (1-3) | 15 (25.0) | 43 (70.0) | 27 (45.0) | |
Moderete pain (4-6) | 37 (61.7) | 15 (25.0) | 2 (3.3) | |
Severe pain (7-10) | 8 (13.3) | 2 (3.3) | - | |
aPain scores according to the visual analogue scale ranging from 0 to 10; SD indicates standard deviation | ||||
Surgeries | Number (%) | Satisfactory outcomes n (%) |
Primary surgery (n=24) |
|
|
Upper plexus | 6 (25) | 5 (83) |
Pan-palsy | 18 (75) | 6 (33) |
All | 24 (100) | 11 (46) |
Secondary Surgery (n=26) |
|
|
Shoulder deformity | 15 (58) | 13 (87) |
Wrist and forearm deformity | 11 (42) | 6 (54) |
All | 26 (100) | 19 (73) |
Primary and secondary surgery | 50 (100) | 30 (60) |
Mallet score 14 to 25 or Raimondi score 2-3 or Medical Research grading >3 to 5. | ||
Narakas classification | Total 200 (100%) | Grade-1 72 (36%) | Grade-2 64 (32%) | Grade-3 50 (25%) | Grade-4 14 (7%) |
Complete recoverya | 107 (54) | 60 (83) | 40 (63) | 7 (14) | - |
Near complete functional recovery but partial deformitya | 22 (11) | 5 (7) | 10 (16) | 6 (12) | 1 (7) |
Partial recovery with gross functional defect and deformity | 31 (16) | 7 (10) | 13 (20) | 10 (20) | 1 (7) |
No significant improvement | 40 (20) | - | 1 (1.5) | 27 (54) | 12 (86) |
aSatisfactory recovery bGrade 1, C5, 6, 7 improvement; Grade 2, C5, 6, 7 improvement; Grade 3, panpalsy C5, 6, 7,8,9, Grade 4, panpalsy with Hornon’s syndrome. | |||||
Trials | Groups | ||||
NC | SC | ColC | Pre-SwE Exp | Post-SwE Exp | |
1 | 20.8 (0.6) | 22.1 (1.8) | 41.1 (1.3)b | 31.9 (1.9)b | 32.9 (1.8)a, b |
2 | 10.9 (0.6) | 14.9 (1.7) | 37.4 (1.1)b | 24.9 (2.0)b | 26.8 (2.5)b |
3 | 8.4 (0.5) | 9.9 (2.0) | 32.8 (1.2)b | 22.0 (1.4)b | 21.0 (1.4)b |
4 | 7.8 (0.5) | 10.4 (1.3) | 27.6(1.1)b | 12.8 (1.2)b | 13.0 (1.4)b |
Savings (%)c | 47.7 (3.0) | 33.0 (3.0) | 10.0 (0.9)b | 23.6 (2.7)b | 18.9 (5.3)b |
NC indicates normal control; SC, Sham control; ColC, colchicine control; SwE, swimming exercise exposure. aP <0.05; bP <0.01. cThe difference in latency scores between trials 1 and 2, expressed as the percentage of savings increased from trial 1 to trial 2 | |||||


Lesion-size | Histopathology report | Total | |||||
CIN1 | CIN2 | CIN3 | ICC | CC | SM | ||
0–5 mm | 73 | 0 | 0 | 0 | 5 | 5 | 83 |
6–15 mm | 119 | 18 | 1 | 4 | 0 | 0 | 142 |
>15 mm | 1 | 8 | 31 | 23 | 12 | 0 | 75 |
Total | 193 | 26 | 32 | 27 | 17 | 5 | 300 |
CIN indicates cervical intraepithelial neoplasia; ICC, invasive cervical cancer; CC, chronic cervicitis; SM, squamous metaplasia | |||||||
| Histopathology report | Total | ||||||
CIN1 | CIN2 | CIN3 | ICC | CC | SM | |||
Lesion -Size | 0-5 mm | 73 | 0 | 0 | 0 | 5 | 5 | 83 |
6-15 mm | 119 | 18 | 1 | 4 | 0 | 0 | 142 | |
>15 mm | 1 | 8 | 31 | 23 | 12 | 0 | 75 | |
Total | 193 | 26 | 32 | 27 | 17 | 5 | 300 | |
CIN indicates Cervical intraepithelial neoplasia; ICC, Invasive cervical cancer; CC, Chronic cervicitis; SM, Squamous metaplasia | ||||||||
Group | Didactic posttest marks (%) | Flipped posttest marks (%) | Difference in marks (mean improvement) | P |
<50% | 63.2 (9.4) | 82.2 (10.8) | 19.0 | <0.001 |
≥50% | 72.4 (14.9) | 84.2 ( 10.3) | 11.8 | <0.001 |
Data presented as mean (standard deviation) | ||||








